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Abstract. With the rapid advancements in cancer research, the infor-
mation that is useful for characterizing disease, staging tumors, and cre-
ating treatment and survivorship plans has been changing at a pace that
creates challenges when physicians try to remain current. One example
involves increasing usage of biomarkers when characterizing the patho-
logic prognostic stage of a breast tumor. We present our semantic tech-
nology approach to support cancer characterization and demonstrate it
in our end-to-end prototype system that collects the newest breast can-
cer staging criteria from authoritative oncology manuals to construct an
ontology for breast cancer. Using a tool we developed that utilizes this
ontology, physician-facing applications can be used to quickly stage a new
patient to support identifying risks, treatment options, and monitoring
plans based on authoritative and best practice guidelines. Physicians can
also re-stage existing patients or patient populations, allowing them to
find patients whose stage has changed in a given patient cohort. As new
guidelines emerge, using our proposed mechanism, which is grounded by
semantic technologies for ingesting new data from staging manuals, we
have created an enriched cancer staging ontology that integrates relevant
data from several sources with very little human intervention.
Keywords: ontologies, knowledge integration, deductive inference, au-
tomatic extraction, cancer characterization, cancer staging guidelines
Resource: https://cancer-staging-ontology.github.io
1 Introduction
Our goal is to improve health knowledge infrastructures by use of semantic tech-
nologies to support data integration in an environment of quickly evolving med-
ical information. We present a prototype system that uses semantic technologies
to integrate medical information relevant for characterizing breast cancer. Our
system can automatically parse the guidelines from the cancer staging manual
and construct OWL axioms [3] that can be used to infer recommended person-
alized options for patients. These inferences are made using the data related to
the treatment and monitoring of the disease that are represented in RDF [19].
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1.1 Background
The authoritative staging system is published by the American Joint Committee
on Cancer (AJCC). As the inaugural authors of the cancer staging manuals have
stated in [2]:
“Staging of cancer is not an exact science. As new information becomes
available about etiology and various methods of diagnosis and treatment,
the classification and staging of cancer will change.”
Since the inception of the cancer staging manual in 1977, there have been
eight editions. The latest AJCC Cancer Staging Manual, Eighth Edition (AJCC
8th Edition)[1], makes a tangible effort to incorporate biologic and molecular
markers to create a more contemporary personalized approach using pathologic
prognostic staging. This has increased the complexity of the staging criteria.
In order to stage tumors, many physicians rely on cancer staging manuals,
or compact ‘cheat sheets’ derived from the contents of these manuals. However,
since the new staging guideline incorporates additional data streams, the physi-
cians have to traverse increasingly tedious decision trees.
In terms of discovering relevant treatment and monitoring options based on
the stage, or more broadly the characterization of the disease, physicians usually
refer to the National Comprehensive Cancer Network (NCCN) Guidelines [18].
Navigating these guidelines also is often a tedious process. Furthermore, in order
to keep up with the growing and rapidly changing body of knowledge, physicians
may also use subscription services such as UpToDate1, which has articles on
many of the state of the art topics in medicine, including cancer. However,
physicians may not have enough time to sift through these articles and ascertain
the information that is relevant for the case at hand.
1.2 Related Work
Initial work related to an ontology that captured cancer staging information is
available in Massicano et al. [21] for the AJCC 6th edition [27]. Boeker et al.
[5] have also created an ontology for the same guideline in which they focus
on tumors in the colon and rectum. The biggest difference between the previous
ontologies and our cancer staging ontology is the inclusion of additional biomark-
ers as per the AJCC 8th edition staging criteria, which were not available in the
previous staging editions. These biomarkers used in the new edition significantly
increased the complexity of the criteria required to stage a tumor. Additionally,
the previous ontologies do not model real-world representations of the tumor
concepts in their axioms nor specify those in the comments. In those ontologies,
the tumor is of a certain rdf:type T (class representing severity of tumor size:
T0 -T4 ), N (class representing the severity of the spread to the lymph nodes:
N0 -N3 ) and M (class representing whether the cancer has metastasized: M0 -
M1 ). In the real world, representation for tumor size T has a value in millimeters
1 UpToDate - a clinical decision support resource: http://www.uptodate.com
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(or centimeters) that is used to derive a T value of 0-4. Similarly, N has a value
for the number of lymph nodes affected that is used to derive the severity rating
from 0-3. Thus, their approach of representing the cancer characterization using
just the rdf:type to the corresponding T, N, M classes is problematic because
when any of these derived classifications change as per a new guideline, the RDF
graph has to change with it, representing the new classification. In our knowl-
edge graph, these values are encoded as attributes to give them temporal extent,
avoiding this problem.
Furthermore, in addition to including classes for all cancer stages for the re-
spective guideline, we also map the breast cancer terms to community-accepted
terms from the National Cancer Institute thesaurus (NCIt) [12], and incorpo-
rate recommended tests and treatment plans from the openly reusable Clinical
Interpretations of Variants in Cancer (CIViC) [14] data that can be used to pro-
vide stage specific recommendations. Furthermore, our ontology includes terms
that are not included in NCIt or AJCC, such as more specific subclasses of tu-
mor characteristics (T1, T1 as, T1 am, T1NOS, etc.) that are available in the
Surveillance, Epidemiology, and End Results (SEER) dataset [16].
1.3 Overview of the Knowledge Integration System for Breast
Cancer Characterization
We developed our prototype primarily to address the issue of rapidly changing
information in characterizing disease, specifically breast cancer. Since manual
look-up of the breast cancer staging criteria is prone to human error, our sys-
tem was designed to support automated navigation through the tedious decision
trees to minimize any look up errors. We also provide support for integration
of data from various sources. Fig. 1 depicts the overall knowledge integration
architecture that will be explained in detail in the following sections.
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Fig. 1. Knowledge Integration Architecture for Breast Cancer Characterization
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2 Development of the Cancer Staging Ontologies
As mentioned in related work (Section 1.2) the last known staging ontologies were
created for the AJCC 6th edition. There are no ontologies for the AJCC 7th and
8th editions to the best of our knowledge. We describe the process we followed
when constructing these new staging ontologies, accounting for the complexity
of the data streams in the new guideline.
2.1 Cancer Staging Terms
The previous breast cancer staging guidelines (i.e. AJCC 7th edition [10] and
earlier) only considered anatomical features such as the size of the tumor (T), the
number of lymph nodes affected (N), and whether the cancer has metastasized
(M). Additionally considered in the new staging guidelines [1] are biomarkers
including human epidermal growth factor receptor 2 (HER2), estrogen (ER) and
progesterone (PR) receptor statuses and tumor grade (Grade). This addition
has led to a more complex set of rules for staging criteria using the classes
corresponding to the specific stages in the AJCC 7th and 8th editions that we
incorporated into our Cancer Staging Terms (CST) ontology.
Fig. 2 depicts the 8th staging edition staging class hierarchy. Each stage class
includes the properties cst:hasRecommendedTest, cst:hasTreatmentOption, and
rdfs:subClassOf assertions where applicable. We added the rdfs:comments to
better describe the concepts in the ontology based on the descriptions available
in the medical literature and to support explanation.
Fig. 2. Stage Hierarchy of the AJCC Cancer Staging 8th Edition
Furthermore, in the AJCC staging manuals, and in the data we ingested from
other sources, we observed different subclasses for the broader classification of the
features considered, i.e. T, N, M, HER2, ER, PR, and Grade in the ontology. Fig.
3 depicts a small subset of these classifications, which includes various Tumor size
(T) classes. Similarly, there are other subclass assertions, and mappings to the
NCIt classes for N, M, HER2, ER, PR, and Grade. We augmented these classes
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with the rdfs:comment, rdfs:labels, and the owl:equivalentClass obtained from
NCIt [12]. These rdfs:comments and rdfs:labels are used to explain a particular
conclusion resulting from the application of a reasoner utilizing the ontology
explained in detail in Section 5.
Fig. 3. Hierarchy of the Tumor Size (T) Classes in Our Integrated Ontology. We created
the tumor size classes in the left two columns to support our integration and reasoning.
These classes reflect content in SEER [16] and not AJCC [1].
2.2 Translating Staging Criteria into Structured Mappings
We extracted 19 criteria from AJCC 7th edition, and 407 criteria for clinical
prognostic stage grouping from AJCC 8th edition. A script was necessary for
the 8th edition since the complexity of the staging guideline has increased with
the addition of the biomarkers. Table 1 illustrates the number of different combi-
nations for staging criteria observed in the two staging guidelines. The non-linear
expansion of the number of combinations is due to the complex interaction of
the additional biomarkers HER2, ER, PR and Tumor Grade.
Stage 0 IA IB IIA IIB IIIA IIIB IIIC IV
AJCC 7th Edition 1 1 2 3 2 5 3 1 1
AJCC 8th Edition 1 57 33 77 39 82 92 25 1
Table 1: Number of Feature Combinations for Determining Stage
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For each of the two staging guidelines, we created corresponding ‘map files’
to represent the conditions required for a tumor to be classified a certain stage
from 0-IV. We created 18 such map files for the two guidelines (AJCC 7th and
8th editions), with 9 map files representing each stage from 0, IA, IB, IIA, IIB,
IIIA, IIIB, IIIC, and IV. Each line in the map file in a 7th edition stage contains
the set of possible T, N and M combinations that would result in that stage
being assigned to the tumor. The map files for the 8th edition followed a similar
form, but also included the additional features HER2, ER, PR and Grade.
If any of the features can be any value for a tumor to be staged, the map
file omitted those corresponding features, and only included the features that
mattered. For example, in order for a tumor to be classified stage IV in both
the guidelines, the only criteria necessary was the ‘M’ (whether the cancer has
metastasized) to be true. Regardless of any other combinations of the other
features T, N in the 7th edition, and additionally HER2, ER, PR and Grade
in the 8th edition, the tumor will always be classified stage IV, thus only one
combination is available for both the guidelines for determining stage IV.
2.3 Structured Mappings to Ontology
In order to automatically generate OWL axioms for the staging criteria, we
utilized the map files created in Section 2.2. These map files were parsed using
a script, where the property owl:intersectionOf was leveraged in creating the
axioms. For example, in order for a tumor to be classified as Stage IA in the
AJCC 7th edition (i.e. AJCC7 Stage IA), a tumor profile must satisfy the axiom
in Listing 2.1. However, for the same tumor to be classified as Stage IA in the
AJCC 8th edition (i.e. AJCC8 Stage IA), only one of the 57 axioms must be
satisfied (Listing 2.2 demonstrates one such axiom). We developed the breast
cancer staging ontology for the AJCC 7th edition (BCS7) and the ontology for
the AJCC 8th edition (BCS8) using the above-mentioned procedure to codify all
the axioms related to classifying tumors.
@prefix cst: <http :// idea.tw.rpi.edu/cancer_staging_terms.owl#> .
[] a owl:Class; rdfs:subClassOf cst:AJCC7_Stage_IA;
owl:intersectionOf ( cst:T1 cst:N0 cst:M0 ).
Listing 2.1. The Only OWL Axiom for a Tumor to be Classified as Stage IA in the
AJCC 7th Edition
[] a owl:Class; rdfs:subClassOf cst:AJCC8_Stage_IA;
owl:intersectionOf ( cst:T1 cst:N0 cst:M0 cst:Grade1
cst:HER2_Neg cst:ER_Neg cst:PR_Pos ).
...
Listing 2.2. One of the Many OWL Axioms for a Tumor to be Classified as Stage IA
in the AJCC 8th Edition
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3 Integrated Cancer Knowledge Graph
We chose RDF [19] as the underlying knowledge representation model to han-
dle heterogeneous data while providing interoperable representations. The CST,
BCS7 and BCS8 developed in Section 2, are part of our Integrated Cancer Knowl-
edge Graph. Additionally, we extracted data from crowd sourced, open source,
reusable cancer resources to augment the knowledge graph with treatment and
monitoring options based on the stage inferred using the cancer staging ontolo-
gies developed.
3.1 Integrating Data from Other Cancer Data Sources
There are many services that provide vast collections of data that may be useful
and relevant in a cancer knowledge graph. Some of these services include CIViC
[14], OncoKB [6], MyCancerGenome [23] and Integrative Onco Genomics [13].
As a proof of concept, we incorporated data from CIViC [14], which has crowd
sourced, open source and reusable data that identifies drugs that may interact
with biomarkers. Additionally from the CIViC data dumps, related articles and
their trust ratings captured in the form of provenance were also incorporated.
Nanopublications [24] were created for this data using a semantic annotation
approach called Semantic Data Dictionaries (SDDs) [25], which simplifies the
ability to express the full semantics of a dataset. The SDD process [25] allowed
us to link the data concepts with each other, as well as reference implicit entities
in the data, and link the corresponding data elements as characteristics of these
entities. The concepts contained in the data records needed to be mapped with
related terms from domain specific ontologies such as NCI thesaurus (NCIt) [12]
and Uniprot [7], as well as general purpose ontologies such as Semanticscience
Integrated Ontology (SIO) [9].
The dictionary mapping table of the SDD that was used for CIViC maps 14
different features in the dataset such as Drugs, Status, Evidence ID, Evidence
Level, Gene, Variant, Disease and the Trust Rating to the respective classes
available in SIO and NCIt. These classes are used for type assignment when
creating a knowledge graph from the data. For example, the Drug column in the
dataset is mapped to sio:Drug, Gene column to sio:Gene, etc. Furthermore, the
classes specified in the attributeOf, inRelationTo and wasDerivedFrom are used
in semantically modeling relationships in the generated nanopublications.
A codebook was used to map over 200 specific values found in the CIViC
data to the corresponding terms in existing ontologies. The Disease types that
were found in CIViC were mapped to concepts in the Human Disease Ontol-
ogy (DOID) [26], Experimental Factor Ontology (EFO) [20], and NCIt [12].
For example, the concept for the HER2-receptor Positive Breast Cancer in our
knowledge graph is mapped to concepts such as efo:1000294, doid:0060079,
ncit:C53556 2. Similarly, drugs were mapped to concepts from the Drug Bank
[29], the Drug Ontology (DRON) [15], and/or Chemical Entities of Biological
Interest (ChEBI) Ontology [8], genes were mapped to terms in Uniprot [7], etc.
2 These specific mappings were looked up using Ontobee (http://www.ontobee.org).
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4 Converting Patient Records to RDF
In order to evaluate our cancer staging ontology, we needed cancer patient data
that included the characteristics of the tumor in RDF, ideally in the nanopub-
lications format [24]. The SEER datasets [16] contained the desired data which
included demographic information, tumor stage as per the older AJCC 6th edi-
tion, and the survival status of patients treated from 1980-2012. We browsed the
datasets using the statistical software, SEER*Stat3, and downloaded a subset of
the data to create the patient nanopublications.
Due to the anonymity and privacy constraints on the medical data, the SEER
patient records lacked any identifying information like the patient name. How-
ever, for our use case, i.e. to model a patient, we needed an identifying attribute,
so we annotated the patient records with names from Python’s Natural Language
Toolkit (NLTK) name corpus [4] to assign a name to each patient record. The
patient data was then fed through the SDD pipeline [25] to generate knowledge
graphs that included nanopublications that captured the attributes of a pa-
tient and where that information came from within an assertion in the patient
graph. Utilization of the SDD approach allowed us to semantically represent re-
lationships such as the age of patient at diagnosis (i.e. the attribute sio:Age as
sio:attributeOf the patient which sio:existsAt the time of diagnosis). We mapped
29 such features for a patient record in the SEER dataset in the data dictionary,
and the codebook contains 100+ mappings to terms in NCIt.
Since some of the values occurring in SEER did not match existing terms in
the ontologies, we leveraged our Cancer Staging Terms (CST) ontology, intro-
duced in Section 2. A codebook mapping corresponding to SEER was defined
that would generate standard values and map commonly occurring terms to
their ontology equivalents. As the structured format of the data is insufficient to
capture the implicit linkages within the attributes of the dataset, a SEER dic-
tionary mapping was defined that established the entity-attribute mappings to
facilitate the conversion of the data to the named graphs with nanopublications.
5 Inference Agent
We developed a deductive inference agent on the Whyis knowledge graph frame-
work [22] to infer the stage of a tumor, and the corresponding treatment/mon-
itoring plans. Whyis provides an environment for automated generalized infer-
ence over changes to the knowledge graph, supporting the generation of derived
knowledge. The framework enables knowledge curation using a Semantic Ex-
tract, Transform, and Load tool for creating RDF from tabular sources, as well
as automated mapping of external linked data knowledge sources. Furthermore,
developers can create custom views for visualizing the data in the underlying
knowledge graph.
The Whyis inference agent was built to reason over the nanopublications
pertaining to the patient data records constructed in Section 4, using the cancer
3 SEER*Stat: https://seer.cancer.gov/seerstat
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staging ontologies CST, BCS7 and BCS8 introduced in Section 2. While the
SDD process [25] allowed us to model the data easily, it resulted in some chal-
lenges in terms of writing inference rules in OWL, such as finding appropriate
paths between entities or attributes specific to the nanopublications, as well as
inference over individuals rather than just classes. To address these issues, we
decided to take a route similar to SPARQL DL [28] and built SPARQL templates
for different OWL reasoning profiles, as well as custom inference rules based on
the SDD files, to be consumed by the inference agent.
An example configuration for an OWL inference rule is shown in Listing
5.1, and an example custom rule, auto-generated with the utilization of files
generated by the SDD process is shown in Listing 5.2.
"Class Subsumption Closure ": (
where = "? resource rdfs:subClassOf ?class .
?class rdfs:subClassOf+ ?superClass .",
construct ="? resource rdfs:subClassOf ?superClass .",
explanation ="Since {{class }} is a subclass of {{ superClass }},
any class that is a subclass of {{ class}} is also a subclass
of {{ superClass }}. Therefore , {{ resource }} is a subclass of
{{ superClass }}.")
Listing 5.1. Example Configuration for an OWL Inference Rule (Class Subsumption))
"AJCC8 Stage IIIA": (
resource ="? Tumor",
prefixes ="..." ,
construct ="? Tumor cst:hasAJCCStage cst:AJCC8_Stage_IIIA .",
where=tnm_where +
?T rdf:type cst:T3 .
?N rdf:type cst:N3 .
?M rdf:type cst:M0 .
?Grade rdf:type cst:Grade1 .
?HER2 rdf:type cst:HER2_Pos .
?ER rdf:type cst:ER_Pos .
?PR rdf:type cst:PR_Pos .
Listing 5.2. Example Configuration for a Custom Inference Rule (One of the Criteria
for a Tumor to be Classified as Stage IIIA in the AJCC 8th Edition)
These configurations are used to instantiate the following variables in the
inference agent: resource, prefixes, where, construct and explanation. The
prefixes and where variables are used in a SPARQL query that selects relevant
URIs from the triple store. The resource variable is used to refer to which
element returned by the query will be appended new triples. The form of the new
triples that will be added is specified in the construct variable. An explanation
for the rule creating this new knowledge is specified in the explanation variable.
Generating Explanations
Our data conversion process captures the provenance of the various sources,
which we convert to nanopublications, as well as the explanations behind why
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specific assertions were inferred. These natural language explanations make it
easier for a non-technical user, who might not have an in-depth knowledge of the
staging rules, to understand why a certain stage was inferred. When an explicit
explanation is not provided in the rule, it is derived from the where clause
used to create the assertion corresponding to the inference. The explanation is
then associated with that assertion on the new inferred stage using the prov:used
property. As an example, when the custom inference rule specified in Listing 5.2
is fired on Patient D, whose tumor satisfies the criteria given in the where clause
in that rule, an explanation similar to the one shown in Listing 5.3 will be gen-
erated. For better readability of the explanation, the rdfs:label or rdfs:comment
of the values that get bound to variables such as ?T,?N,?M, etc. (i.e. ‘Primary
Tumor size’, ‘Degree of spread to lymph nodes’, ‘Presence of distant metastasis’,
etc.) are used instead of the actual class names.
Patient D’s tumor was found to be AJCC8 Stage IIIA since the
following are true:
- Primary Tumor size is T3 .
- Degree of spread to lymph nodes is N3 .
- Presence of distant metastasis is M0 .
- Tumor Grade is Grade3 .
- Human Epidermal growth factor Receptor 2 (HER2) is Positive.
- Estrogen Receptor (ER) is Positive.
- Progesterone Receptor (PR) is Positive.
Listing 5.3. Example of Explanation for Inferring a Stage in the AJCC 8th Edition
Using a similar strategy, we are able to identify possible drug treatment plans
from the cancer database CIViC by equating the disease type that the drugs
target, to the inferred cancer stage of the patient. To achieve this, we generated
custom inference rules from the CIViC SDD files, and once the inferencer runs
these rules on the patient nanopublications, the corresponding explanations were
generated and attached to the stage assertion nanopublications.
6 Visualization of the Cancer Characterization
In order to demonstrate the integrated cancer knowledge graph and the reason-
ing capabilities of the Whyis inference agent, we built a visualization tool that
displays different treatment paths and guideline impacts to a patient in the form
of interactive reports as introduced by Kennedy et al. [17]. The visualization is
built on the Whyis knowledge graph framework (introduced in Section 5). When
a user, say a physician, selects a patient record, they are presented with informa-
tion that helps enhance their diagnostic process, and in some cases, eliminates
the manual labor of walking through the decision trees in the guidelines to sup-
port cancer staging decisions. As can be seen in the Fig. 4 and Fig. 5, the view
is divided into four sections: (1) Patient Details, (2) Biomarker and Staging, (3)
Treatment Plan, and (4) Suggested Drugs.
In this visualization tool, it is possible to choose between the three latest
AJCC staging guidelines, i.e. AJCC 6th, 7th, and 8th editions. Once a guideline
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Fig. 4. AJCC 7th Edition Staging Char-
acterization
Fig. 5. AJCC 8th Edition Staging Charac-
terization
is selected, the view dynamically loads newly derived knowledge using asyn-
chronous JavaScript SPARQL POST requests. The derived knowledge includes
the inferred stage, whether this is an up-stage/down-stage/no-change, and the
explanations behind the inferred stage. Based on the inferred stage for the guide-
line selected, the corresponding treatment and monitoring options available in
our integrated cancer knowledge graph (i.e. CIViC drug nanopublication records)
are also queried and presented to the user.
A screenshot of a patient’s report as per the older 7th edition is shown in Fig.
4, and the same patient’s report according to the newer 8th edition is shown in
Fig. 5. Note the differences in the inferred stage–the patient is down-staged from
IIIA in the 7th edition to IIB in the 8th edition. There are also some changes to
the treatment and monitoring options based on this new inferred stage.
7 Evaluation
We used our cancer staging ontologies and the inference agent on 250 randomly
selected SEER patient records to estimate prevalence of stage changes between
different staging guidelines. We anticipated a number of changes given that the
latest AJCC 8th edition utilizes additional biomarkers to determine stage. These
SEER patient records were first transformed into nanopublications using the
SDD process [25] as explained in Section 4, after which our inference agent was
applied to determine the stage as per the two guidelines.
The aggregated view of these stage transitions from the AJCC 7th to the
8th edition is shown in Fig. 6. As can be seen in the figure, a majority of the
patients’ stage did not change, but a statistically significant percentage of pa-
tients were either up-staged or down-staged. For example, out of the patients
who were assigned to have stage IIB cancer according to the 7th edition (19%
of the population), 15% were down-staged to IB, 30% were reclassified to IIA,
38% remained in stage IIB, and 13% and 5% were up-staged to IIIA and IIIB
respectively.
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Fig. 6. Stage Transitions of 250 Patient Records from SEER
This indicates that there is a strong need for re-characterizing breast cancer
according to the new guideline. Our ontologies and the supporting tools provide
the first step in this process.
8 Discussion
We have utilized semantic technologies for all aspects of our system: from char-
acterizing breast cancer and representing synthetic patient data to loading struc-
tured and unstructured treatment and monitoring data into a knowledge graph.
For the integrated cancer knowledge graph generation, we mapped concepts
in several datasets using a codebook and modeled a structure amongst the at-
tributes using the dictionary mapping table. The deductive inference agent we
developed leverages SPARQL DL reasoning, where queries are used to select
existing triples and construct new triples. This was done over common inference
rules including class subsumption and class or property equivalence closures, as
well as custom rules pertaining to the cancer staging. The inference was ap-
plied to heterogeneous data sources in our integrated cancer knowledge graph
to seamlessly derive new knowledge by applying the inference rules. The visu-
alization we created is able to react to changes in the triple store that results
in automatic updates to what the user is seeing. The information in our cancer
knowledge graph is kept current with periodic semantic extract transform load
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updates. Our system allows one to consider a multitude of parameters related
to tumor biology as well as standard pathology simultaneously and can easily
updated to support new classification criteria.
Resource Contributions
We expect the following publicly available artifacts, along with the applicable
documentation, to be useful resources for anyone interested in analyzing breast
cancer data according to the new and the old cancer staging guidelines.
1. Ontologies:
(a) Cancer Staging Terms (CST)
(b) Breast Cancer Staging Ontol-
ogy for the AJCC 7th Edition
(BCS7)
(c) Breast Cancer Staging Ontol-
ogy for the AJCC 8th Edition
(BCS8)
2. Semantic Annotations:
(a) Semantic Data Dictionaries
(b) Code Books
(for SEER and CIViC)
3. Source Code:
(a) AJCC Guideline Extractor
(b) OWL Axiom Generator
(c) Whyis Inference Agent
(d) Custom Inference Rules
(e) Visualization
4. Data:
(a) SEER Nanopublications
(b) CIViC Nanopublications
9 Future Work
There are many online resources with rapidly changing information from clin-
ical trials, as well as data from basic science research with useful cancer data
that can be leveraged to augment the cancer knowledge graph. However, when
multiple data streams are combined, especially drug information, there may be
inconsistent or ambiguous information. Therefore, we will need to resolve such
issues using a combination of provenance, data integrity, and trust in the source
and/or the methodology.
The inference agent we developed can be used to identify treatment paths
based on a patient’s cancer stage. However, the CIViC data [14] we used for this
purpose defines treatment paths for the broader stages (i.e. stage II as opposed
to AJCC’s narrower IIA or IIB stages). Therefore, we plan to ascertain the cor-
rect treatment paths for all the narrower stages and add those in to the cancer
knowledge graph. We plan to incorporate additional data sources such as the
NCCN clinical practice guidelines in oncology [18], which is the authoritative
source for physicians in identifying suitable cancer treatment and monitoring
plans. This will allow our inference agent to output the precise treatment paths,
in addition to the ones that are obtained by linking the patient’s inferred nar-
rower AJCC tumor stage to the broader stage with ontological properties such
as rdfs:subClassOf relationships. We also expect the future ontologies to be built
using the AJCC API as a resource for all valid values on stage permutations.
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We plan to expand the inference capabilities, which are currently restricted
to class, instance, property subsumption, equivalence, and inversion closures,
to other techniques that will help derive even more relevant knowledge. For
example, we believe it would be useful to infer ‘patients like me’ using instance
matching and identify alternate treatment paths that have worked in the past
for similar patients, and predict response to a treatment path using temporal
reasoning.
As new guidelines will infer new staging results, updates or fixes to the patient
data or existing guidelines are needed. The Whyis framework provides an effec-
tive mechanism to ‘retire’ old inferences and trigger computation of new ones, as
long as the nanopublication has the same URI. The framework tracks a nanop-
ublication URI when a new version is added, removing older versions, as well as
any inferences that are made on them. We opted to create different classes for the
stage based on the guideline, so that we can switch between different guidelines
easily. For example, we have AJCC7 Stage IIA and AJCC8 Stage IIA, as op-
posed to a generic Stage IIA. Therefore, encoding the information about which
guideline the staging criteria is from, in the provenance assertion for that triple,
without having to make that explicit class, and utilizing the provenance infor-
mation in the inference to determine the stage per the selected guideline is a
useful addition. This change requires versioning of assertions in our integrated
cancer knowledge graph, and some changes to the custom inference rules.
10 Conclusion
We have presented a prototype knowledge integration system that can be used
to encapsulate the breadth of information required to characterize disease. The
specific domain problem we address is characterizing breast cancer, which today
is predominantly done by manually looking up cancer staging guidelines. In fact,
oncology is moving towards adopting the concept of Precision Oncology, in which
the treatment plans and therapies are driven by data from personalized genetic
markers independent of cancer type [11]. In the future, new guidelines for cancer
staging are expected to incorporate genomic test results analyzed in the context
of the patient’s history, which will further increase the complexity of the staging
criteria, requiring automated mechanisms similar to the techniques illustrated
in this paper. Therefore, it is our expectation that the resources contributed in
this paper and the methodologies to ingest rapidly changing information, will
be useful to application designers who are aiming to support next generation
precision medicine assistant tools.
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